Ocular Therapeutix to Attend Major Investor Conferences
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical leader focused on transforming the retina experience, has announced its participation in two major investor conferences scheduled for March. This engagement reflects the company's commitment to driving awareness and investment in their innovative therapies.
Upcoming Events: TD Cowen Conference
The first conference is the TD Cowen 45th Annual Health Care Conference. It will take place on March 4, where Ocular Therapeutix will engage in a fireside chat. The session is slated for 11:50 AM ET, providing an opportunity for attendees and investors to gain insights directly from the company’s Executive Chairman, President, and CEO, Dr. Pravin U. Dugel.
Engaging Discussion at Leerink Partners Global Healthcare Conference
Following this, Ocular Therapeutix will participate in the Leerink Partners Global Healthcare Conference on March 10. The fireside chat is set for 10:00 AM ET, where Dr. Dugel will again discuss the company’s advancements and direction. Both events highlight the company’s strategic focus on enhancing visibility within the investment community.
Webcast Access for Investors
For those unable to attend in person, there will be a live webcast available. Investors can access this through the Ocular Therapeutix website within the Events and Presentations section found on the Investor Relations page, ensuring that stakeholders can stay informed about the dialogue surrounding the company's pivotal treatments.
Ocular Therapeutix: Revolutionizing Retina Treatments
Ocular Therapeutix is dedicated to redefining treatment options for retinal diseases. Their product AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI) is pioneering a new standard of care. Currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), this treatment represents a significant advancement in ocular health.
Innovations in Their Treatment Pipeline
Additionally, the company has integrated its proprietary ELUTYX™ bioresorbable hydrogel-based formulation technology across various products. This includes DEXTENZA, which is an FDA-approved corticosteroid aimed at treating ocular inflammation and pain following surgeries, as well as PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), currently in a Phase 2 clinical trial aimed at managing open-angle glaucoma and ocular hypertension.
Following Ocular Therapeutix
Investors and interested parties are encouraged to follow Ocular Therapeutix on their official website, LinkedIn, or X for the latest updates, innovations, and insights. They continue to push boundaries in ocular therapeutics, affirming their role as a leader in the biopharmaceutical space.
Contact Information for Investors and Media Inquiries
For any media or investor inquiries, Bill Slattery, Vice President of Investor Relations at Ocular Therapeutix, is available to provide insights and details. He can be reached via email at bslattery@ocutx.com.
Frequently Asked Questions
What is Ocular Therapeutix?
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing innovative therapies for retinal diseases.
What conferences will Ocular Therapeutix participate in?
They will attend the TD Cowen Annual Health Care Conference and the Leerink Partners Global Healthcare Conference in March.
Who will present at the conferences?
Dr. Pravin U. Dugel, the Executive Chairman, President, and CEO, will be presenting at both events.
How can I access the live webcasts?
The live webcasts for the conferences can be accessed through the Ocular Therapeutix Investor Relations page.
What is AXPAXLI?
AXPAXLI is an investigational treatment for wet age-related macular degeneration currently in Phase 3 clinical trials.
